Trial Profile
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Emapalumab (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Registrational; Therapeutic Use
- Sponsors Light Chain Bioscience; Swedish Orphan Biovitrum
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.
- 10 Jun 2021 Status changed from recruiting to active, no longer recruiting.